topiramate · Azurity · NDA 214679
Eprontia
Earliest generic entry, as listed
21 Aug 2040
Blocked by patent: US 11433046, US 11433046, US 11433046, US 11633374, US 11826343, US 11911362, US 11911362, US 11911362, US 12290503, US 12290503, US 12290503.
Listed patents · 11 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11433046 | use U-3413 | 21 Aug 2040 |
| US 11433046 | use U-3414 | 21 Aug 2040 |
| US 11433046 | use U-3415 | 21 Aug 2040 |
| US 11633374 | product | 21 Aug 2040 |
| US 11826343 | product | 21 Aug 2040 |
| US 11911362 | product, use U-3413 | 21 Aug 2040 |
| US 11911362 | product, use U-3414 | 21 Aug 2040 |
| US 11911362 | product, use U-3415 | 21 Aug 2040 |
| US 12290503 | product, use U-3413 | 21 Aug 2040 |
| US 12290503 | product, use U-3414 | 21 Aug 2040 |
| US 12290503 | product, use U-3415 | 21 Aug 2040 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214679 · 001 · RLD | solution, oral | 25MG/ML | 21 Aug 2040 |